Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:DYAI NASDAQ:IMA NASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.80+1.9%$0.76$0.38▼$115.57$9.26M0.711.50 million shs115,032 shsDYAIDyadic International$0.97+0.5%$0.95$0.71▼$2.20$35.18M0.9482,858 shs71,742 shsIMAImageneBio$9.01-1.4%$14.32$7.95▼$23.28$36.22M0.517,302 shs19,469 shsMDCXMedicus Pharma$2.47+2.5%$2.44$1.79▼$8.94$44.02MN/A236,269 shs281,974 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+2.21%+1.56%-8.39%-98.55%DYAIDyadic International0.00%+6.25%+29.21%+3.97%-22.02%IMAImageneBio0.00%+14.82%-35.63%-45.98%-54.93%MDCXMedicus Pharma0.00%+28.19%+22.96%-9.40%+240,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.80+1.9%$0.76$0.38▼$115.57$9.26M0.711.50 million shs115,032 shsDYAIDyadic International$0.97+0.5%$0.95$0.71▼$2.20$35.18M0.9482,858 shs71,742 shsIMAImageneBio$9.01-1.4%$14.32$7.95▼$23.28$36.22M0.517,302 shs19,469 shsMDCXMedicus Pharma$2.47+2.5%$2.44$1.79▼$8.94$44.02MN/A236,269 shs281,974 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+2.21%+1.56%-8.39%-98.55%DYAIDyadic International0.00%+6.25%+29.21%+3.97%-22.02%IMAImageneBio0.00%+14.82%-35.63%-45.98%-54.93%MDCXMedicus Pharma0.00%+28.19%+22.96%-9.40%+240,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0047,144.09% UpsideDYAIDyadic International 3.00Buy$6.00526.30% UpsideIMAImageneBio 2.50Moderate Buy$35.50294.01% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50859.18% UpsideCurrent Analyst Ratings BreakdownLatest AEON, MDCX, DYAI, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DYAIDyadic InternationalCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/2/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/13/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$25.00 ➝ $23.007/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ADYAIDyadic International$3.42M10.13N/AN/A$0.08 per share11.98IMAImageneBio$9.16M3.95N/AN/A$31.33 per share0.29MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.084.23N/AN/AN/AN/A-994.63%N/ADYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)IMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/AMDCXMedicus Pharma-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%11/28/2025 (Estimated)Latest AEON, MDCX, DYAI, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/11/2025Q2 2025MDCXMedicus Pharma-$0.39-$0.43-$0.04-$0.43N/AN/A7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22DYAIDyadic International5.402.022.02IMAImageneBioN/A13.5213.52MDCXMedicus PharmaN/A1.291.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%DYAIDyadic International27.95%IMAImageneBio75.00%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%DYAIDyadic International29.50%IMAImageneBio5.94%MDCXMedicus Pharma11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableDYAIDyadic International736.19 million25.51 millionOptionableIMAImageneBio704.02 million3.78 millionNot OptionableMDCXMedicus PharmaN/A17.82 million15.82 millionN/AAEON, MDCX, DYAI, and IMA HeadlinesRecent News About These CompaniesMedicus Pharma Appoints Carolyn Bonner as Acting CFOSeptember 12 at 5:30 PM | tipranks.comMedicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development PipelineSeptember 11, 2025 | tipranks.comMedicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development PipelineSeptember 11, 2025 | theglobeandmail.comMedicus Pharma Ltd. Advances Clinical Trials for Skin Cancer TreatmentSeptember 10, 2025 | tipranks.comMedicus Pharma says UAE SKNJCT-004 Phase 2 trial commences patient recruitmentSeptember 9, 2025 | msn.comMedicus Pharma Ltd. Advances Clinical Trials for Skin Cancer TreatmentSeptember 8, 2025 | tipranks.comMedicus Pharma begins Phase 2 clinical study in UAE to treat BCCSeptember 8, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)September 8, 2025 | accessnewswire.comAMedicus Pharma Ltd. (NASDAQ: MDCX) Builds Momentum With Antev Acquisition and Pipeline ProgressSeptember 5, 2025 | theglobeandmail.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalSeptember 4, 2025 | americanbankingnews.comMedicus Pharma closes Antev acquisition; sees $6B market potentialSeptember 2, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Completes Acquisition of Antev LimitedSeptember 2, 2025 | newsfilecorp.comNMedicus Pharma nears FDA milestone in cancer trial - ICYMIAugust 30, 2025 | proactiveinvestors.comMedicus Pharma Completes Equity Sales to YorkvilleAugust 22, 2025 | msn.comMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of ...August 21, 2025 | finance.yahoo.comMedicus Pharma Advances D-MNA Clinical Program and Expands Strategic PartnershipsAugust 21, 2025 | tipranks.comMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial HighlightsAugust 21, 2025 | newsfilecorp.comNBiotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)August 20, 2025 | theglobeandmail.comBiotech’s Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)August 19, 2025 | theglobeandmail.comMedicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion MoveAugust 7, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, MDCX, DYAI, and IMA Company DescriptionsAEON Biopharma NASDAQ:AEON$0.80 +0.02 (+1.92%) Closing price 03:58 PM EasternExtended Trading$0.79 -0.01 (-0.63%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Dyadic International NASDAQ:DYAI$0.97 +0.01 (+0.53%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.ImageneBio NASDAQ:IMA$9.01 -0.13 (-1.42%) As of 03:55 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Medicus Pharma NASDAQ:MDCX$2.47 +0.06 (+2.49%) As of 03:57 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
